While no statistical differences in parasitemia levels were observed early in the ascending phase, more than 90% reduction in malaria parasitemia was observed at days 16 and 19 after the challenge in mice vaccinated with the MVA-CSP/IL15 construct compared to the other groups. Here, IL15 is linked to parasitic infectious disease.